Constant currency profit excluding one-off items increased by $900 million (£674 million) to $18.9 billion (£14.2 billion), with a strong performance in international wealth and premier banking and ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.52; value investors should ...

On April 30, GSK plc (NYSE:GSK) reported strong financial performance in its fiscal Q1 2025 results, with its oncology sales surging by 53%.

For new and old investors, taking full advantage of the stock market and investing with confidence are ... which is more than double the S&P 500's performance over the same time frame. However, the ...